Skip to content

Precigen PGEN Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.82M+12.2%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's debt issuance cost amortization?
Precigen (PGEN) reported debt issuance cost amortization of $345K in Q1 2026.
What is the long-term trend for Precigen's debt issuance cost amortization?
Over 2 years (2021 to 2024), Precigen's debt issuance cost amortization has grown at a -100.0% compound annual growth rate (CAGR), from $11.74M to $0.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).